What changed
Added the sponsor's December 2025 NDA submission while preserving the separation between submission, FDA review, approval, and product identity.
Source record · Phase 3 trial and official regulatory records · reviewed July 26, 2026
Phase 3 evidence and an application submission are not FDA approval.
The circulating claim“CagriSema finished Phase 3, so cagrilintide products are basically approved.”
What the source record says
REDEFINE 1 is a real, large phase 3 trial of coadministered cagrilintide and semaglutide. Novo Nordisk announced an FDA application submission in December 2025, but neither cagrilintide nor CagriSema is an FDA-approved U.S. drug product as of the July 26 review.
Why the claim misleads
A positive phase 3 result, an application submission, FDA review, approval of a defined product, and identity of an unrelated product are being treated as one milestone.
Correction
Phase 3 evidence and an application submission are not FDA approval.
Primary sources
Garvey et al., 2025 — REDEFINE 1Open source ↗Novo Nordisk — CagriSema NDA submissionOpen source ↗FDA concerns with unapproved GLP-1 drugsOpen source ↗Cagrilintide / CagriSema library entryOpen source ↗What would change our answer
An FDA approval, complete response, or other official action would change the dated U.S. status. New peer-reviewed trials could change confidence for a specific outcome. Neither would authenticate an unrelated product without product-level evidence.
Version history · 2 entries
Boundary: This check evaluates a public claim. It does not assess an individual product or person and is not treatment, dosing, sourcing, or legal advice.